Discontinued — last reported Q2 '17
Analog Devices Long-Term Debt - Fair Value decreased by 0.3% to $7.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 99.9%, from $6.22T to $7.52B. Over 4 years (FY 2021 to FY 2025), Long-Term Debt - Fair Value shows an upward trend with a 502.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_value| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.67B | $7.15B | $6.36T | $5.66T | $5.83T | $5.47B | $5.82T | $5.77T | $5.60T | $5.30B | $5.65T | $6.68T | $6.91T | $6.25B | $6.22T | $5.82T | $7.48T | $7.54B | $7.52B |
| QoQ Change | — | +26.0% | >999% | -11.1% | +3.0% | -99.9% | >999% | -0.8% | -3.0% | -99.9% | >999% | +18.1% | +3.5% | -99.9% | >999% | -6.3% | +28.4% | -99.9% | -0.3% |
| YoY Change | — | — | — | — | >999% | -23.4% | -8.6% | +2.0% | -4.0% | -3.2% | -2.8% | +15.7% | +23.5% | +18.0% | +9.9% | -12.8% | +8.2% | +20.6% | -99.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.